Getting the e-Patient Equipped and Engaged

Patients often search the internet for medical answers and solutions before talking to their healthcare provider (HCP). This article provides practice pearls for conversing with…

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Myths and Misunderstandings – The Rationale and Evidence for the Screening and Treatment of Pediatric Dyslipidemia

Landmark autopsy studies have demonstrated that atherosclerosis begins in youth and is associated with numerous cardiovascular disease (CVD) risk factors, including dyslipidemia.(1,2) Having fewer cardiometabolic…

Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association

Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association

Motivational Interviewing to Promote Behavior Change

Best Biomarkers for Inflammation

Atherosclerosis is widely recognized as a chronic inflammatory disorder. Therapies with anti-inflammatory effects in patients with an increased inflammatory status can reduce cardiovascular events, as…

High-sensitivity C-reactive Protein Versus Coronary Artery Calcium Scoring: Dissecting a Biological Target from a Cardiovascular Risk Assessment Tool

Cardiovascular disease (CVD) remains the leading cause of mortality across the globe. The cornerstones of CVD prevention and treatment are accurate risk assessment — such…

A Glimpse at Lipodystrophy – Diagnosis and Treatment

Lipodystrophies are a group of disorders of fat tissue loss that are classified according to whether the condition is genetic or acquired and by the…